European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact
Guidelines

Upper Urinary Tract Urothelial Cell Carcinoma

Want to read the guideline in your own time? Download the PDF

Download full guideline

Looking for a quick overview? Check the pocket guidelines.

Download pocket guidelines
Full text guidelineSummary of ChangesPublications & AppendicesPanelRelated content
No results found
  1. Introduction
  2. Methods
  3. Epidemiology Aetiology And Pathology
  4. Staging And Classification Systems
  5. Diagnosis
  6. Risk Stratification
  7. Disease Management
  8. Follow Up
  9. Quality Indicators For The Management Of Utuc
  10. References
  11. Conflict Of Interest
  12. Citation Information
  13. Copyright And Terms Of Use
8. Follow Up
  • 1. Introduction
  • 2. Methods
  • 3. Epidemiology Aetiology And Pathology
  • 4. Staging And Classification Systems
  • 5. Diagnosis
  • 6. Risk Stratification
  • 7. Disease Management
  • 8. Follow Up
  • 9. Quality Indicators For The Management Of Utuc
  • 10. References
  • 11. Conflict Of Interest
  • 12. Citation Information
  • 13. Copyright And Terms Of Use
  • No elements found. Consider changing the search query.
  • List is empty.

8. FOLLOW UP

The aims for follow-up after treatment for UTUC are to comply with patient rehabilitation needs, to detect recurrent or new primary tumours within the urothelium, and to detect regional and/or distant metastases. Bladder recurrence is not considered a distant recurrence. Unfortunately, the heterogeneity of available studies on disease-recurrence in UTUC is significant, and recommendations on follow-up have a low level of evidence at best.

After previous RNU for low-risk tumours, bladder follow-up should adopt the NMIBC follow-up protocol for low-risk disease, a cystoscopy at three months post-operatively, a subsequent cystoscopy nine months later and yearly cystoscopies for five years [288]. Screening for metastases during follow-up is not mandatory. Due to the low risk of contralateral upper tract recurrence, routine imaging should be discussed on an individual basis [289].

When RNU has been performed for high-risk tumours, stringent follow-up is mandatory to detect metachronous bladder tumours (probability increases over time [290]), local recurrence, and distant metastases. The risk of bladder recurrence is higher in patients with previous history of bladder cancer compared to those without, indicating the need for more intensive cystoscopy follow-up [291]. The risk of bladder recurrences and other-site recurrences decreases significantly four years after RNU, suggesting that less vigorous annual cystoscopies and cross-sectional imaging including CT urographies thereafter may apply [291].

After kidney-sparing management for low-risk UTUC, and where no subsequent upstaging or upgrading occurred after the early second-look ureteroscopy after six to eight weeks [154] or was found in the resection specimen after segmental ureteric resection, cystoscopy and CT-urography should be carried out at three and six months, and then yearly for five years. The risk for bladder recurrences beyond five years is low after endoscopic treatment and segmental ureterectomy [292,293].

In patients treated with kidney-sparing for high-risk tumours, the indication (imperative vs. non-imperative) affects the surveillance regimen by the consequences of recurrent disease. Still, the ipsilateral UUT requires careful and long-term follow-up due to the high risk of disease recurrence [153,294,295] and progression following RNU, even beyond five years [296].

Surveillance regimens are based on CT urography, cystoscopy and urinary cytology [290,297]. There are, however, several unanswered questions related to the optimal follow-up of patients treated for both low-risk and high-risk UTUC, of which some are:

  • The added value of new urinary markers compared to cytology in voided urine samples in high-risk patients [298].
  • The effect of the Paris System on sensitivity and specificity of voided and selective urinary cytology during follow-up of UTUC in high-risk tumours [299].
  • If adjuvant upper tract instillations have been administered after endourologic kidney-sparing management, will that allow for less vigorous follow-up?
  • The role of ureteroscopies of the ipsilateral upper urinary tract during follow-up after endourologic kidney-sparing treatment vs. CT urography and voided urinary cytology.

Additionally, it is not known how patients with Lynch syndrome, without and with UTUC, should be screened or followed long-term given the inadequacy of surveillance based on urinalysis for nonvisible haematuria [300] and urine cytology [301], particularly in those individuals who are MSH2 mutation carriers [53] and those who already have developed a UTUC. Section 8.1 presents the summary of evidence and recommendations for follow-up of UTUC.

8.1. Summary of evidence and recommendations for the follow-up of UTUC

Summary of evidenceLE
Follow up should be based on risk stratification and the type of treatment.3
RecommendationsStrength rating
After radical nephroureterectomy
Low-risk tumours
Perform cystoscopy at three months. If negative, perform subsequent cystoscopy 9 months later and then yearly, for 5 years.Weak
High-risk tumours
In patients with previous history of NMIBC perform cystoscopy and voided urinary cytology at 3 months. If negative, repeat subsequent cystoscopy and cytology every 3 months for a period of 2 years, and every 6 months thereafter until 5 years, and then yearly.Weak
In patients without previous history of NMIBC perform cystoscopy and voided urinary cytology at 3 months. If negative, repeat subsequent cystoscopy and cytology every 6 months for a period of 2 years, and every year thereafter until 5 years.Weak
Perform computed tomography (CT) urography and chest CT every 6 months for 2 years, and then yearly.Weak
After kidney-sparing management
Low-risk tumours
For bladder follow-up perform cystoscopy 3 and 6 months, and then yearly for 5 years.Weak
For upper tract follow-up, after negative second look URS, perform cross sectional imaging urography at 3 and 6 months and then yearly for 5 years with or without URS*.Weak
High-risk tumours
In patients without previous history of NMIBC follow-up the same as for high-risk tumours after RNU.Weak
For upper tract follow-up, after negative second look URS, perform cross sectional imaging urography and URS at 3 and 6 months and then cross sectional imaging urography every 6 months for 2 years and then every year for 5 years, with or without URS*.Weak

*The role of ureteroscopies of the ipsilateral upper urinary tract during follow-up after endourologic kidney-sparing treatment vs. CT urography and voided urinary cytology is unknown.

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer